Kerstin B. Kaufmann

Kerstin B. Kaufmann

Auto-generated profile, based on publicly available information

Kerstin B. Kaufmann

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2016 in Science
Verified
Journal Article
Closed access
PDF file
FNFaiyaz Notta
Faiyaz Notta
SZSasan Zandi
Sasan Zandi
NTNaoya Takayama
Naoya Takayama
SDStephanie Dobson
Stephanie Dobson
OGOlga I. Gan
Olga I. Gan
JDJohn E. Dick
John E. Dick
Adjusting hematopoietic hierarchy: In adults, more than 300 billion blood cells are replenished daily. This output arises from a cellular hierarchy where stem cells differentiate into a series of multilineage progenitors, culminating in unilineage progenitors that generate over 10 different mature blood cell types. Notta et al. mapped the lineage potential of nearly 3000 single cells from 33 different cell populations of stem and progenitor cells from fetal liver, cord blood, and adult bone marrow (see the Perspective by Cabezas-Wallscheid and Trumpp). Prenatally, stem cell and progenitor populations were multilineage with few unilineage progenitors. In adults, multilineage cell potential was only seen in stem cell populations. Science , this issue p. 10.1126/science.aab2116 ; see also p. 126

10 October 2014 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
ALAya Ludin
Aya Ludin
SGShiri Gur-Cohen
Shiri Gur-Cohen
KGKarin Golan
Karin Golan
KKKerstin B. Kaufmann
Kerstin B. Kaufmann
TITomer Itkin
Tomer Itkin
TLTsvee Lapidot
Tsvee Lapidot
Significance: Blood forming, hematopoietic stem cells (HSCs) mostly reside in the bone marrow in a quiescent, nonmotile state via adhesion interactions with stromal cells and macrophages. Quiescent, proliferating, and differentiating stem cells have different metabolism, and accordingly different amounts of intracellular reactive oxygen species (ROS). Importantly, ROS is not just a byproduct of metabolism, but also plays a role in stem cell state and function. Recent Advances: ROS levels are dynamic and reversibly dictate enhanced cycling and myeloid bias in ROS high short-term repopulating stem cells, and ROS low quiescent long-term repopulating stem cells. Low levels of ROS, regulated by intrinsic factors such as cell respiration or nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) activity, or extrinsic factors such as stem cell factor or prostaglandin E2 are required for maintaining stem cell self-renewal. High ROS levels, due to stress and inflammation, induce stem cell differentiation and enhanced motility. Critical Issues: Stem cells need to be protected from high ROS levels to avoid stem cell exhaustion, insufficient host immunity, and leukemic transformation that may occur during chronic inflammation. However, continuous low ROS production will lead to lack of stem cell function and opportunistic infections. Ultimately, balanced ROS levels are crucial for maintaining the small stem cell pool and host immunity, both in homeostasis and during stress situations. Future Directions: Deciphering the signaling pathway of ROS in HSC will provide a better understanding of ROS roles in switching HSC from quiescence to activation and vice versa, and will also shed light on the possible roles of ROS in leukemia initiation and development. Antioxid. Redox Signal. 21, 1605–1619.

24 October 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TPthe St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project
JZJinghui Zhang
Jinghui Zhang
KMKelly McCastlain
Kelly McCastlain
HYHiroki Yoshihara
Hiroki Yoshihara
BXBeisi Xu
Beisi Xu
CMCharles G Mullighan
Charles G Mullighan

17 September 2013 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KKKerstin B. Kaufmann
Kerstin B. Kaufmann
HBHildegard Büning
Hildegard Büning
AGAnne Galy
Anne Galy
ASAxel Schambach
Axel Schambach
MGManuel Grez
Manuel Grez
The first gene therapy clinical trials were initiated more than two decades ago. In the early days, gene therapy shared the fate of many experimental medicine approaches and was impeded by the occurrence of severe side effects in a few treated patients. The understanding of the molecular and cellular mechanisms leading to treatment‐ and/or vector‐associated setbacks has resulted in the development of highly sophisticated gene transfer tools with improved safety and therapeutic efficacy. Employing these advanced tools, a series of Phase I/II trials were started in the past few years with excellent clinical results and no side effects reported so far. Moreover, highly efficient gene targeting strategies and site‐directed gene editing technologies have been developed and applied clinically. With more than 1900 clinical trials to date, gene therapy has moved from a vision to clinical reality. This review focuses on the application of gene therapy for the correction of inherited diseases, the limitations and drawbacks encountered in some of the early clinical trials and the revival of gene therapy as a powerful treatment option for the correction of monogenic disorders.

1 February 2016 in Cancer Cell
Verified
Journal Article
Open access
ELEric R. Lechman
Eric R. Lechman
BGBernhard Gentner
Bernhard Gentner
SNStanley W.K. Ng
Stanley W.K. Ng
ESErwin M. Schoof
Erwin M. Schoof
PGPeter van Galen
Peter van Galen
JDJohn E. Dick
John E. Dick
To investigate miRNA function in human acute myeloid leukemia (AML) stem cells (LSC), we generated a prognostic LSC-associated miRNA signature derived from functionally validated subpopulations of AML samples. For one signature miRNA, miR-126, high bioactivity aggregated all in vivo patient sample LSC activity into a single sorted population, tightly coupling miR-126 expression to LSC function. Through functional studies, miR-126 was found to restrain cell cycle progression, prevent differentiation, and increase self-renewal of primary LSC in vivo. Compared with prior results showing miR-126 regulation of normal hematopoietic stem cell (HSC) cycling, these functional stem effects are opposite between LSC and HSC. Combined transcriptome and proteome analysis demonstrates that miR-126 targets the PI3K/AKT/MTOR signaling pathway, preserving LSC quiescence and promoting chemotherapy resistance.

1 November 2019 in Cell Stem Cell
Verified
Journal Article
Open access
SXStephanie Z. Xie
Stephanie Z. Xie
LGLaura Garcia-Prat
Laura Garcia-Prat
VVVeronique Voisin
Veronique Voisin
RFRobin Ferrari
Robin Ferrari
OGOlga I. Gan
Olga I. Gan
JDJohn E. Dick
John E. Dick
Cellular stress responses serve as crucial decision points balancing persistence or culling of hematopoietic stem cells (HSCs) for lifelong blood production. Although strong stressors cull HSCs, the linkage between stress programs and self-renewal properties that underlie human HSC maintenance remains unknown, particularly at quiescence exit when HSCs must also dynamically shift metabolic state. Here, we demonstrate distinct wiring of the sphingolipidome across the human hematopoietic hierarchy and find that genetic or pharmacologic modulation of the sphingolipid enzyme DEGS1 regulates lineage differentiation. Inhibition of DEGS1 in hematopoietic stem and progenitor cells during the transition from quiescence to cellular activation with N-(4-hydroxyphenyl) retinamide activates coordinated stress pathways that coalesce on endoplasmic reticulum stress and autophagy programs to maintain immunophenotypic and functional HSCs. Thus, our work identifies a linkage between sphingolipid metabolism, proteostatic quality control systems, and HSC self-renewal and provides therapeutic targets for improving HSC-based cellular therapeutics.